Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions

By L. Capuron, Jane F. Gumnick, D. Musselman, D. Lawson, Andrea Reemsnyder, C. Nemeroff, Andrew H. Miller. Neuropsychopharmacology, 2002

745 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Depressive disorders and immunity: 20 years of progress and discovery. (2007, background): “…characterized by the typical symptoms of depression such as depressed mood, anxiety, irritability, memory and attentional disturbance, develops usually between the first and third month of IFN-a therapy in vulnerable patients (Musselman et al., 2001; Capuron et al., 2002; Capuron et al., 2004).”
Inflammation-Associated Depression: From Serotonin to Kynurenine (2010, background): “Capuron et al. observed a linear relationship between decreased plasma tryptophan levels and scores of depression after 26 days of immunotherapy in cancer patients (Capuron et al 2002b).”
Immune System to Brain Signaling: Neuropsychopharmacological Implications (2011, background): “As discussed in more detail below, impaired tryptophan/serotonin metabolism was found to be involved in the development of IFN-alpha-induced mood and cognitive symptoms (Capuron et al., 2002b; Capuron et al., 2003a; Raison et al., 2010b).”
From Stress to Inflammation and Major Depressive Disorder: A Social Signal Transduction Theory of Depression (2014, background): “Raz Yirmiya, in turn, was among the first to show that cytokines can directly elicit depressive symptoms and that symptoms elicited in this way can be alleviated with antidepressant medications (Yirmiya et al., 1999, 2000; see also Musselman et al., 2001, and Capuron et al., 2002).”